Chemical Structure (Toviaz 01)
Toviaz Tablet, Film Coated, Extended Release
Product Images NDC 0069-0244
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 0069-0244). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Toviaz 02)
The text describes a figure (Figure 1) that shows the mean change from baseline in the number of micturitions per 24 hours in a study (Study 1). The study examined the effect of a drug called Toviaz (in two different doses) compared to a placebo. The data are presented in three different time points: 2, 8, and 12 weeks. The number of participants in each group (Placebo, Toviaz 4mg, and Toviaz 8mg) is provided.*
Figure 2 (Toviaz 03)
The text describes a figure with three lines representing the mean change from baseline for different treatments on urge incontinence episodes per 24 hours over a period of 12 weeks. The treatments are a placebo, Toviazdmg, and Toviaz8mg. There are 211 participants in the placebo group, 199 in the Toviazdmg group, and 223 in the Toviaz8mg group.*
Figure 3 (Toviaz 04)
The text describes a figure showing the change in the number of micturitions (urination) per day over a period of 12 weeks in a study that had three groups: a placebo group with 266 participants, a group taking Toviaz4mg with 267 participants, and a group taking Toviaz8mg with 267 participants. The figure shows the mean change from baseline.*
Figure 4 (Toviaz 05)
The text describes a graph showing the mean change in urge incontinence episodes per 24 hours over the course of a study. The study had four different groups, including a placebo group and three groups taking different doses of the medication Toviaz. The graph displays results from week 0, week 2, week 8, and week 12 of the study.*
Logo (Toviaz 06)
Pfizer Labs, a division of Pfizer Inc. located in New York City (zip code 10017), distributes products related to healthcare.*
Logo (Toviaz 07)
This is a label indicating that the product is distributed by Pfizer Labs, a division of Pfizer Inc., based in New York, NY 10017.*
Principal Display Panel (4 mg Tablet Bottle Label)
This is a description of a medication called Toviaz, which is distributed by Pfizer Labs. The medication comes in the form of extended-release tablets and is prescribed for use in treating urinary disorders. The tablets should be stored between 15°C to 30°C and protected from moisture. The prescription is available in 4mg and is only available with a prescription. The text includes the medicine's National Drug Code (NDC) number and manufacturing information.*
Principal Display Panel (8 mg Tablet Bottle Label)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
